Systemic corticosteroids
PreclinicalSmall molecule
Merck & Co.Systemic corticosteroids is one of 50 small molecule programs targeting Ankylosing Spondylitis. It is currently in Preclinical.
1
Indications
5
Total Trials
2
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
114 competitors in Ankylosing Spondylitis
#DrugCompanyPhaseTrials
1Bimzelx
UCBPhase 3
Jyseleca
GileadPhase 3
Arcoxia
NovartisPhase 3
Actemra
RochePhase 3
Stelara
Johnson & JohnsonPhase 3
Otezla
AmgenPhase 3
Taltz
Eli LillyPhase 3
Xeljanz
PPrism Pharmaceuticals
Phase 3
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Anjeso
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Recurrence1 trial
Steroid1 trial
How Long Should we Give Steroids for Patients With Severe PCP
Not yet recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT07328984·416 enrolled
Ankylosing Spondylitis1 trial
Characteristics of Ankylosing Spondylitis Associated Uveitis
Completed·—··NCT07113834·22 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Systemic corticosteroids. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company